Brolucizumab as Good as Aflibercept for Neovascular AMD Brolucizumab as Good as Aflibercept for Neovascular AMD

Brolucizumab is noninferior to aflibercept and requires less-frequent injections for patients with neovascular age-related macular degeneration (nAMD), according to results from two phase-3 trials.Reuters Health Information
Source: Medscape Ophthalmology Headlines - Category: Opthalmology Tags: Ophthalmology News Source Type: news